Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients. Issue 2 (15th April 2019)

• Record Type: Journal Article
• Authors: Johansson, Sofie Lock; Wulf-Johansson, Helle; Schlosser, Anders; Titlestad, Ingrid L.; Miller, Bruce; Tal-Singer, Ruth; Holmskov, Uffe; Vestbo, Jørgen; Sørensen, Grith Lykke
• Is Part Of: ERJ open research. Volume 5:Issue 2(2019)
• Publication Date: 2019-04-15
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; Respiration; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Respiratory Tract Diseases; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.2005
• DOI: 10.1183/23120541.00021-2019
• Languages: English
• ISSNs: 2312-0541

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by chronic airflow limitation and inflammation of the airways and lung parenchyma. COPD is associated with many comorbidities, especially cardiovascular disease (CVD), which share similar risk factors with COPD [1]. Circulating MFAP4 is a relevant biomarker to identify COPD patients at risk of death and cardiovascular comorbidity after smoking cessation http://ow.ly/6vnL30o8t1g